News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
695,774 Results
Type
Article (39535)
Company Profile (247)
Press Release (655992)
Section
Business (204109)
Career Advice (2008)
Deals (35415)
Drug Delivery (94)
Drug Development (81005)
Employer Resources (172)
FDA (16156)
Job Trends (14842)
News (345052)
Policy (32496)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (5)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2546)
Accelerated approval (2)
Adcomms (20)
Allergies (80)
Alliances (49368)
ALS (81)
Alzheimer's disease (1345)
Antibody-drug conjugate (ADC) (107)
Approvals (16157)
Artificial intelligence (225)
Autoimmune disease (13)
Automation (14)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (18)
Biosimilars (100)
Biotechnology (175)
Bladder cancer (56)
Brain cancer (24)
Breast cancer (245)
Cancer (1957)
Cardiovascular disease (147)
Career advice (1674)
Career pathing (29)
CAR-T (139)
Cell therapy (392)
Cervical cancer (17)
Clinical research (65646)
Collaboration (758)
Compensation (446)
Complete response letters (18)
COVID-19 (2580)
CRISPR (34)
C-suite (203)
Cystic fibrosis (98)
Data (1896)
Decentralized trials (2)
Denatured (16)
Depression (36)
Diabetes (241)
Diagnostics (6326)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (109)
Drug pricing (95)
Drug shortages (25)
Duchenne muscular dystrophy (84)
Earnings (86121)
Editorial (31)
Employer branding (21)
Employer resources (146)
Events (111571)
Executive appointments (626)
FDA (17241)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (681)
Gene editing (94)
Generative AI (18)
Gene therapy (270)
GLP-1 (677)
Government (4377)
Grass and pollen (4)
Guidances (48)
Healthcare (18803)
Huntington's disease (22)
IgA nephropathy (21)
Immunology and inflammation (101)
Indications (26)
Infectious disease (2708)
Inflammatory bowel disease (131)
Inflation Reduction Act (8)
Influenza (46)
Intellectual property (83)
Interviews (311)
IPO (16484)
IRA (40)
Job creations (3628)
Job search strategy (1423)
Kidney cancer (9)
Labor market (34)
Layoffs (448)
Leadership (15)
Legal (7900)
Liver cancer (70)
Lung cancer (287)
Lymphoma (129)
Machine learning (2)
Management (58)
Manufacturing (264)
MASH (59)
Medical device (13315)
Medtech (13320)
Mergers & acquisitions (19395)
Metabolic disorders (619)
Multiple sclerosis (67)
NASH (16)
Neurodegenerative disease (75)
Neuropsychiatric disorders (24)
Neuroscience (1805)
NextGen: Class of 2025 (6512)
Non-profit (4476)
Northern California (2384)
Now hiring (37)
Obesity (336)
Opinion (201)
Ovarian cancer (71)
Pain (75)
Pancreatic cancer (76)
Parkinson's disease (130)
Partnered (18)
Patents (199)
Patient recruitment (93)
Peanut (46)
People (57051)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20444)
Phase II (28911)
Phase III (21541)
Pipeline (959)
Podcasts (44)
Policy (107)
Postmarket research (2563)
Preclinical (8648)
Press Release (64)
Prostate cancer (91)
Psychedelics (30)
Radiopharmaceuticals (243)
Rare diseases (350)
Real estate (5901)
Recruiting (65)
Regulatory (22108)
Reports (46)
Research institute (2316)
Resumes & cover letters (349)
Rett syndrome (3)
RNA editing (2)
RSV (37)
Schizophrenia (61)
Series A (120)
Series B (77)
Service/supplier (11)
Sickle cell disease (49)
Southern California (2058)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (28)
Startups (3571)
State (2)
Stomach cancer (12)
Supply chain (59)
The Weekly (25)
United States (20831)
Vaccines (652)
Venture capitalists (37)
Webinars (12)
Weight loss (224)
Women's health (33)
Worklife (15)
Date
Today (102)
Last 7 days (564)
Last 30 days (2665)
Last 365 days (33506)
2025 (7624)
2024 (35222)
2023 (40076)
2022 (51174)
2021 (55712)
2020 (54084)
2019 (46538)
2018 (35019)
2017 (32117)
2016 (31488)
2015 (37561)
2014 (31327)
2013 (26346)
2012 (28571)
2011 (29265)
2010 (27328)
Location
Africa (719)
Alabama (49)
Alaska (7)
Arizona (223)
Arkansas (13)
Asia (37689)
Australia (6162)
California (5436)
Canada (1853)
China (465)
Colorado (244)
Connecticut (256)
Delaware (123)
Europe (80809)
Florida (809)
Georgia (190)
Idaho (57)
Illinois (488)
India (23)
Indiana (288)
Iowa (9)
Japan (138)
Kansas (100)
Kentucky (23)
Louisiana (7)
Maine (60)
Maryland (822)
Massachusetts (4085)
Michigan (208)
Minnesota (366)
Mississippi (2)
Missouri (75)
Montana (27)
Nebraska (25)
Nevada (56)
New Hampshire (62)
New Jersey (1546)
New Mexico (28)
New York (1560)
North Carolina (908)
North Dakota (7)
Northern California (2384)
Ohio (190)
Oklahoma (14)
Oregon (33)
Pennsylvania (1237)
Puerto Rico (9)
Rhode Island (26)
South America (1095)
South Carolina (18)
South Dakota (1)
Southern California (2058)
Tennessee (92)
Texas (809)
Utah (163)
Virginia (127)
Washington D.C. (57)
Washington State (506)
West Virginia (3)
Wisconsin (48)
695,774 Results for "santen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Harrow Acquires Santen’s Branded Ophthalmic Portfolio
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of agreements with affiliates of Santen Pharmaceutical Co., Ltd. (“Santen”) under which Harrow will acquire certain U.S. and Canadian commercial rights for the following branded products from Santen:
July 18, 2023
·
15 min read
Press Releases
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
November 8, 2024
·
7 min read
Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America
Santen Pharmaceutical Co., Ltd. announced that it has signed licensing agreements and an asset transfer agreement with two U.S. companies.
July 18, 2023
·
2 min read
Santen Announces Health Canada Approval for Cationorm® Plus to Relieve the Symptoms of Dry Eye and Ocular Allergy
Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), today announced the approval of Cationorm® Plus by Health Canada.
October 6, 2022
·
5 min read
Biotech Bay
Santen’s Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States
Santen’s Verkazia ® (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States.
May 2, 2022
·
4 min read
FDA
Santen and UBE Received FDA Approval for OMLONTI® (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), and UBE Corporation (UBE) today announced that the U.S. Food and Drug Administration (FDA) has approved OMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension.
September 26, 2022
·
7 min read
Press Releases
FOXO TECHNOLOGIES INC. ANNOUNCES EXECUTION OF A NON BINDING AGREEMENT TO ACQUIRE VECTOR BIOSOURCE INC.
March 20, 2025
·
4 min read
Press Releases
Alcon Agrees to Acquire LENSAR, Inc.
March 25, 2025
·
9 min read
Policy
Santen Announces Health Canada Approval of PRESERFLO MicroShunt
Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., Ltd., a global company focused exclusively on ophthalmology, announced the approval of PRESERFLOTM MicroShunt by Health Canada.
May 4, 2021
·
3 min read
Press Releases
SNBL and Tasso, Inc. to Establish Joint Venture in Japan
March 28, 2025
·
2 min read
1 of 69,578
Next
